U.S. Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Indication by Study Design, By Sponsor, By Service, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
U.S. Clinical Trials Market Growth & Trends
The U.S. clinical trials market size is estimated treach USD 57.79 billion by 2030, registering a CAGR of 6.30% from 2025 t2030, according ta new report by Grand View Research, Inc. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.
The number of people diagnosed with cancer is expected tincrease multi-fold in the coming eight years. Although survivors have increased considerably owing tresearch in the oncology field, the number of cancer patients is expected tincrease across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 t3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected tgrow owing tthe disease prevalence across the U.S. thereby boosting the industry’s growth.
The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has alsbeen interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind tminimize risks. Monitoring gadgets, software tools, and mobile phones enable participants tcomplete the experiment from their homes.
U.S. Clinical Trials Market Report Highlights
U.S. Clinical Trials Market Growth & Trends
The U.S. clinical trials market size is estimated treach USD 57.79 billion by 2030, registering a CAGR of 6.30% from 2025 t2030, according ta new report by Grand View Research, Inc. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.
The number of people diagnosed with cancer is expected tincrease multi-fold in the coming eight years. Although survivors have increased considerably owing tresearch in the oncology field, the number of cancer patients is expected tincrease across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 t3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected tgrow owing tthe disease prevalence across the U.S. thereby boosting the industry’s growth.
The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has alsbeen interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind tminimize risks. Monitoring gadgets, software tools, and mobile phones enable participants tcomplete the experiment from their homes.
U.S. Clinical Trials Market Report Highlights
- In 2024, the phase III dominated the market with highest revenue share. These trials are more crucial as they involve 300 t3000 participants and have a longer period of time. Thus, it is the most expensive phase
- By study design, the interventional design segment dominated the U.S. market and accounted for the largest revenue share in 2024.
- Based on indication, the oncology segment held the largest revenue share in 2024. This growth is due tthe growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective
1.9.2. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. U.S. CLINICAL TRIALS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Regulatory Landscape
3.4. Technological Landscape
3.5. Pricing Model Analysis
3.6. Clinical Trial Volume Analysis, 2024
3.7. U.S. Clinical Trials Market Analysis Tools
3.7.1. Porter’s Five Forces Analysis
3.7.2. PESTEL Analysis
3.7.3. COVID-19 Impact Analysis
3.8. Product Pipeline Analysis by Stage
3.8.1. Therapeutics in Development
3.8.2. Vaccines in Development
CHAPTER 4. U.S. CLINICAL TRIALS MARKET: PHASE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2024 & 2030
4.3. Phase I
4.3.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Phase II
4.4.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Phase III
4.5.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Phase IV
4.6.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. U.S. CLINICAL TRIALS MARKET: STUDY DESIGN ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2024 & 2030
5.3. Interventional
5.3.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Observational
5.4.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Expanded Access
5.5.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. U.S. CLINICAL TRIALS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
6.3. Autoimmune/Inflammation
6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. Rheumatoid Arthritis
6.3.2.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Multiple Sclerosis
6.3.3.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. Osteoarthritis
6.3.4.1. Osteoarthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Irritable Bowel Syndrome (IBS)
6.3.5.1. Irritable Bowel Syndrome (IBS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Pain Management
6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Chronic Pain
6.4.2.1. Chronic Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Acute Pain
6.4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Oncology
6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Blood Cancer
6.5.2.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Solid Tumors
6.5.3.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Others
6.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. CNS Conditions
6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Epilepsy
6.6.2.1. Epilepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Parkinson's Disease (PD)
6.6.3.1. Parkinson's Disease (PD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. Huntington's Disease
6.6.4.1. Huntington's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Stroke
6.6.5.1. Stroke Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Traumatic Brain Injury (TBI)
6.6.6.1. Traumatic Brain Injury (TBI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Amyotrophic Lateral Sclerosis (ALS)
6.6.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.8. Muscle Regeneration
6.6.8.1. Muscle Regeneration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.9. Others
6.6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Diabetes
6.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Obesity
6.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Cardiovascular
6.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. Others
6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. U.S. CLINICAL TRIALS MARKET: INDICATION BY STUDY DESIGN ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
7.3. Autoimmune/Inflammation
7.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. Interventional
7.3.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Observational
7.3.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. Expanded Access
7.3.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Pain Management
7.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. Interventional
7.4.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Observational
7.4.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. Expanded Access
7.4.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Oncology
7.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Interventional
7.5.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Observational
7.5.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4. Expanded Access
7.5.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. CNS Conditions
7.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Interventional
7.6.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Observational
7.6.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. Expanded Access
7.6.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Diabetes
7.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.2. Interventional
7.7.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.3. Observational
7.7.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.4. Expanded Access
7.7.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Obesity
7.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.2. Interventional
7.8.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.3. Observational
7.8.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.4. Expanded Access
7.8.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9. Cardiovascular
7.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9.2. Interventional
7.9.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9.3. Observational
7.9.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9.4. Expanded Access
7.9.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10. Others
7.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10.2. Interventional
7.10.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10.3. Observational
7.10.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10.4. Expanded Access
7.10.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. U.S. CLINICAL TRIALS MARKET: SERVICE ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
8.3. Protocol Designing
8.3.1. Protocol Designing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Site Identification
8.4.1. Site Identification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Patient Recruitment
8.5.1. Patient Recruitment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Laboratory Services
8.6.1. Laboratory Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Bioanalytical Testing Services
8.7.1. Bioanalytical Testing Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Clinical Trial Data Management Services
8.8.1. Clinical Trial Data Management Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.9. Others
8.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. U.S. CLINICAL TRIALS MARKET: SPONSOR ESTIMATES & TREND ANALYSIS
9.1. Segment Dashboard
9.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
9.3. Pharmaceutical & Biopharmaceutical Companies
9.3.1. Pharmaceutical & Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4. Medical Device Companies
9.4.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Market Participant Categorization
10.1.1. Market Leaders
10.1.2. Emerging Players
10.2. Market Position Analysis, 2024
10.3. Key Company Profiles
10.3.1. IQVIA
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Fortrea Inc.
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. PAREXEL International Corporation
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Thermo Fisher Scientific Inc.
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Charles River Laboratories
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. ICON Plc
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Wuxi AppTec Inc.
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Medpace
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Syneos Health
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. AstraZeneca
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. Merck & Co.
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Eli Lilly and Company
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Novo Nordisk A/S
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives
10.3.14. Pfizer
10.3.14.1. Company Overview
10.3.14.2. Financial Performance
10.3.14.3. Service Benchmarking
10.3.14.4. Strategic Initiatives
10.3.15. Caidya
10.3.15.1. Company Overview
10.3.15.2. Financial Performance
10.3.15.3. Service Benchmarking
10.3.15.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.1.1. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective
1.9.2. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. U.S. CLINICAL TRIALS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Regulatory Landscape
3.4. Technological Landscape
3.5. Pricing Model Analysis
3.6. Clinical Trial Volume Analysis, 2024
3.7. U.S. Clinical Trials Market Analysis Tools
3.7.1. Porter’s Five Forces Analysis
3.7.2. PESTEL Analysis
3.7.3. COVID-19 Impact Analysis
3.8. Product Pipeline Analysis by Stage
3.8.1. Therapeutics in Development
3.8.2. Vaccines in Development
CHAPTER 4. U.S. CLINICAL TRIALS MARKET: PHASE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2024 & 2030
4.3. Phase I
4.3.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Phase II
4.4.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Phase III
4.5.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Phase IV
4.6.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. U.S. CLINICAL TRIALS MARKET: STUDY DESIGN ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2024 & 2030
5.3. Interventional
5.3.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Observational
5.4.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Expanded Access
5.5.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. U.S. CLINICAL TRIALS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
6.3. Autoimmune/Inflammation
6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. Rheumatoid Arthritis
6.3.2.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Multiple Sclerosis
6.3.3.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. Osteoarthritis
6.3.4.1. Osteoarthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Irritable Bowel Syndrome (IBS)
6.3.5.1. Irritable Bowel Syndrome (IBS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Pain Management
6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Chronic Pain
6.4.2.1. Chronic Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Acute Pain
6.4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Oncology
6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Blood Cancer
6.5.2.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Solid Tumors
6.5.3.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Others
6.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. CNS Conditions
6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Epilepsy
6.6.2.1. Epilepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Parkinson's Disease (PD)
6.6.3.1. Parkinson's Disease (PD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. Huntington's Disease
6.6.4.1. Huntington's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Stroke
6.6.5.1. Stroke Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Traumatic Brain Injury (TBI)
6.6.6.1. Traumatic Brain Injury (TBI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Amyotrophic Lateral Sclerosis (ALS)
6.6.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.8. Muscle Regeneration
6.6.8.1. Muscle Regeneration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.9. Others
6.6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Diabetes
6.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Obesity
6.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Cardiovascular
6.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. Others
6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. U.S. CLINICAL TRIALS MARKET: INDICATION BY STUDY DESIGN ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
7.3. Autoimmune/Inflammation
7.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. Interventional
7.3.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Observational
7.3.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. Expanded Access
7.3.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Pain Management
7.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. Interventional
7.4.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Observational
7.4.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. Expanded Access
7.4.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Oncology
7.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Interventional
7.5.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Observational
7.5.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4. Expanded Access
7.5.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. CNS Conditions
7.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Interventional
7.6.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Observational
7.6.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. Expanded Access
7.6.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Diabetes
7.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.2. Interventional
7.7.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.3. Observational
7.7.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.4. Expanded Access
7.7.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Obesity
7.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.2. Interventional
7.8.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.3. Observational
7.8.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.4. Expanded Access
7.8.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9. Cardiovascular
7.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9.2. Interventional
7.9.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9.3. Observational
7.9.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9.4. Expanded Access
7.9.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10. Others
7.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10.2. Interventional
7.10.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10.3. Observational
7.10.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10.4. Expanded Access
7.10.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. U.S. CLINICAL TRIALS MARKET: SERVICE ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
8.3. Protocol Designing
8.3.1. Protocol Designing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Site Identification
8.4.1. Site Identification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Patient Recruitment
8.5.1. Patient Recruitment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Laboratory Services
8.6.1. Laboratory Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Bioanalytical Testing Services
8.7.1. Bioanalytical Testing Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Clinical Trial Data Management Services
8.8.1. Clinical Trial Data Management Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.9. Others
8.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. U.S. CLINICAL TRIALS MARKET: SPONSOR ESTIMATES & TREND ANALYSIS
9.1. Segment Dashboard
9.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
9.3. Pharmaceutical & Biopharmaceutical Companies
9.3.1. Pharmaceutical & Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4. Medical Device Companies
9.4.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Market Participant Categorization
10.1.1. Market Leaders
10.1.2. Emerging Players
10.2. Market Position Analysis, 2024
10.3. Key Company Profiles
10.3.1. IQVIA
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Fortrea Inc.
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. PAREXEL International Corporation
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Thermo Fisher Scientific Inc.
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Charles River Laboratories
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. ICON Plc
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Wuxi AppTec Inc.
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Medpace
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Syneos Health
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. AstraZeneca
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. Merck & Co.
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Eli Lilly and Company
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Novo Nordisk A/S
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives
10.3.14. Pfizer
10.3.14.1. Company Overview
10.3.14.2. Financial Performance
10.3.14.3. Service Benchmarking
10.3.14.4. Strategic Initiatives
10.3.15. Caidya
10.3.15.1. Company Overview
10.3.15.2. Financial Performance
10.3.15.3. Service Benchmarking
10.3.15.4. Strategic Initiatives
